Emerging Epigenetic Therapeutic Targets in Acute Myeloid Leukemia

Overview

Journal Front Oncol

Specialty Oncology

Date 2019 Sep 26

PMID 31552175

Citations 12

Authors

Bettina Wingelhofer

Tim C P Somervaille

Affiliations

Soon will be listed here.

Abstract

Acute myeloid leukemia (AML) is a genetically heterogeneous malignancy for which treatment options have been largely limited to cytotoxic chemotherapy for the past four decades. Next-generation sequencing and other approaches have identified a spectrum of genomic and epigenomic alterations that contribute to AML initiation and maintenance. The key role of epigenetic modifiers and the reversibility of epigenetic changes have paved the way for evaluation of a new set of drug targets, and facilitated the design of novel candidate treatment strategies. More recently, seven new targeted therapies have been FDA-approved demonstrating successful implementation of the past decades' research. In this review, we will summarize the most recent advances in targeted therapeutics designed for a focused group of key epigenetic regulators in AML, outline their mechanism of action and their current status in clinical development. Furthermore, we will discuss promising new approaches for epigenetic targeted treatment in AML which are currently being tested in pre-clinical trials.

Citing Articles

Advances in epigenetic alterations of chronic lymphocytic leukemia: from pathogenesis to treatment.

Zhang X, Wang H, Zhang Y, Wang X Clin Exp Med. 2024; 24(1):54.

PMID: 38492089 PMC: 10944427. DOI: 10.1007/s10238-023-01268-x.

Small-Molecule Compounds Boost CAR-T Cell Therapy in Hematological Malignancies.

Cao X, Jin X, Zhang X, Utsav P, Zhang Y, Guo R Curr Treat Options Oncol. 2023; 24(3):184-211.

PMID: 36701037 PMC: 9992085. DOI: 10.1007/s11864-023-01049-4.

Targeting BRD9 by I-BRD9 efficiently inhibits growth of acute myeloid leukemia cells.

Zhou L, Yao Q, Li H, Chen J Transl Cancer Res. 2022; 10(7):3364-3372.

PMID: 35116642 PMC: 8797396. DOI: 10.21037/tcr-21-42.

TAF1 inhibitor Bay-299 induces cell death in acute myeloid leukemia.

Zhou L, Yao Q, Ma L, Li H, Chen J Transl Cancer Res. 2022; 10(12):5307-5318.

PMID: 35116379 PMC: 8798726. DOI: 10.21037/tcr-21-2295.

Preclinical Evaluation of a Novel Dual Targeting PI3Kδ/BRD4 Inhibitor, SF2535, in B-Cell Acute Lymphoblastic Leukemia.

Ruan Y, Kim H, Ogana H, Wan Z, Hurwitz S, Nichols C Front Oncol. 2021; 11:766888.

PMID: 34926269 PMC: 8671162. DOI: 10.3389/fonc.2021.766888.

References

Humphrey G, Wang Y, Russanova V, Hirai T, Qin J, Nakatani Y . Stable histone deacetylase complexes distinguished by the presence of SANT domain proteins CoREST/kiaa0071 and Mta-L1. J Biol Chem. 2000; 276(9):6817-24. DOI: 10.1074/jbc.M007372200. View

You A, Tong J, Grozinger C, Schreiber S . CoREST is an integral component of the CoREST- human histone deacetylase complex. Proc Natl Acad Sci U S A. 2001; 98(4):1454-8. PMC: 29278. DOI: 10.1073/pnas.98.4.1454. View

Nakamura T, Mori T, Tada S, Krajewski W, Rozovskaia T, Wassell R . ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol Cell. 2002; 10(5):1119-28. DOI: 10.1016/s1097-2765(02)00740-2. View

Hakimi M, Dong Y, Lane W, Speicher D, Shiekhattar R . A candidate X-linked mental retardation gene is a component of a new family of histone deacetylase-containing complexes. J Biol Chem. 2002; 278(9):7234-9. DOI: 10.1074/jbc.M208992200. View

Iyer N, Ozdag H, Caldas C . p300/CBP and cancer. Oncogene. 2004; 23(24):4225-31. DOI: 10.1038/sj.onc.1207118. View

An W, Kim J, Roeder R . Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53. Cell. 2004; 117(6):735-48. DOI: 10.1016/j.cell.2004.05.009. View

Zhang Y, Zeleznik-Le N, Emmanuel N, Jayathilaka N, Chen J, Strissel P . Characterization of genomic breakpoints in MLL and CBP in leukemia patients with t(11;16). Genes Chromosomes Cancer. 2004; 41(3):257-65. DOI: 10.1002/gcc.20077. View

Pal S, Vishwanath S, Erdjument-Bromage H, Tempst P, Sif S . Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes. Mol Cell Biol. 2004; 24(21):9630-45. PMC: 522266. DOI: 10.1128/MCB.24.21.9630-9645.2004. View

Shi Y, Lan F, Matson C, Mulligan P, Whetstine J, Cole P . Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004; 119(7):941-53. DOI: 10.1016/j.cell.2004.12.012. View

10.

Okada Y, Feng Q, Lin Y, Jiang Q, Li Y, Coffield V . hDOT1L links histone methylation to leukemogenesis. Cell. 2005; 121(2):167-78. DOI: 10.1016/j.cell.2005.02.020. View

11.

Bedford M, Richard S . Arginine methylation an emerging regulator of protein function. Mol Cell. 2005; 18(3):263-72. DOI: 10.1016/j.molcel.2005.04.003. View

12.

Metzger E, Wissmann M, Yin N, Muller J, Schneider R, Peters A . LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature. 2005; 437(7057):436-9. DOI: 10.1038/nature04020. View

13.

Yokoyama A, Somervaille T, Smith K, Rozenblatt-Rosen O, Meyerson M, Cleary M . The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell. 2005; 123(2):207-18. DOI: 10.1016/j.cell.2005.09.025. View

14.

Zhao Y, Lu S, Wu L, Chai G, Wang H, Chen Y . Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol Cell Biol. 2006; 26(7):2782-90. PMC: 1430330. DOI: 10.1128/MCB.26.7.2782-2790.2006. View

15.

Pal S, Baiocchi R, Byrd J, Grever M, Jacob S, Sif S . Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma. EMBO J. 2007; 26(15):3558-69. PMC: 1949000. DOI: 10.1038/sj.emboj.7601794. View

16.

Saleque S, Kim J, Rooke H, Orkin S . Epigenetic regulation of hematopoietic differentiation by Gfi-1 and Gfi-1b is mediated by the cofactors CoREST and LSD1. Mol Cell. 2007; 27(4):562-72. DOI: 10.1016/j.molcel.2007.06.039. View

17.

Cheung N, Chan L, Thompson A, Cleary M, So C . Protein arginine-methyltransferase-dependent oncogenesis. Nat Cell Biol. 2007; 9(10):1208-15. DOI: 10.1038/ncb1642. View

18.

Steger D, Lefterova M, Ying L, Stonestrom A, Schupp M, Zhuo D . DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells. Mol Cell Biol. 2008; 28(8):2825-39. PMC: 2293113. DOI: 10.1128/MCB.02076-07. View

19.

Yokoyama A, Cleary M . Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell. 2008; 14(1):36-46. PMC: 2692591. DOI: 10.1016/j.ccr.2008.05.003. View

20.

Wang L, Pal S, Sif S . Protein arginine methyltransferase 5 suppresses the transcription of the RB family of tumor suppressors in leukemia and lymphoma cells. Mol Cell Biol. 2008; 28(20):6262-77. PMC: 2577430. DOI: 10.1128/MCB.00923-08. View